Neuro2026: The PSP and CBD International Research Symposium

Break

Breakfast, Registration and Poster Set Up

Other

Welcome from CurePSP and PSPA, Patient Perspective

James Cusack, PSPA · Kristophe Diaz, CurePSP · Salin Geevarghese, CurePSP · Jack Phillips, CurePSP

Other

Earlier Diagnosis for PSP and CBD

James Rowe, University of Cambridge

Talk

Early Diagnosis of PSP

Huw Morris, UCL Queen Square Institute of Neurology

Talk

Mixed or Missed? The Spectrum and Impact of Co-Pathologies in PSP and CBD

Gabor Kovacs, University of Toronto

Talk

Clinical Applications of Fluid Biomarkers in PSP: Diagnosis, Prognosis and Trials

Edwin Jabbari, UCL Queen Square Institute of Neurology

Talk

Imaging Biomarkers in PSP Across Research and Clinical Practice

Andrea Quattrone, Magna Graecia University of Catanzaro

Break

Poster and Coffee Break

Other

CBD Session

Yaroslau Compta, University of Barcelona

Talk

Molecular Pathology of Neurodegenerative Disease by Cryo-EM of Amyloid Filaments

Sjors Scheres, MRC Laboratory of Molecular Biology

Talk

The Underlying Pathologies in Corticobasal Syndrome

David Vaughan, UCL Queen Square Institute of Neurology

Talk

SYNAPSE-FTLD: Design of a Basket Trial Including CBS

Alexander Murley, University of Cambridge

Networking

Networking Lunch

Other

Industry Perspectives and Clinical Trials

Kristophe Diaz, CurePSP

Talk

The PSP and CBD Clinical Trial Pipeline

Anne-Marie Wills, Massachusetts General Hospital

Talk

Making Engagement Count: Partnering with the PSP Community in Clinical Development - Lessons Learned from Ferrer’s Partnership with PSP Advocacy Groups

Claudia Roca Herms, Ferrer

Talk

Reflections on the Amylyx ORION Trial: Informing Future PSP Research

Jamie Timmons, Amylyx Pharmaceuticals

Talk

Toolkit for Future PSP Clinical Trials

Tien Dam, Brenig Therapeutics

Panel

Panel Discussion + Q&A

Break

Poster and Coffee Break

Other

Inflammation in Primary Tauopathies

Karen Morrison, PSPA

Talk

Role of Inflammation in PSP and CBD: What We Know Relative to Other More Common Neurodegenerative Diseases and Is It a Therapeutic Target

Malu Tansey, Indiana University School of Medicine

Talk

The Three Ps to Unlock Inflammation in PSP: PET, Peripheral Markers and Postmortem

Maura Malpetti, University of Cambridge

Talk

Astrocytes, Oligodendrocytes, Microglia, and HLA! The Distinct Neuroimmune Landscape of Progressive Supranuclear Palsy

Jessica Rexach, UCLA

Other

Closing Remarks

Kristophe Diaz, CurePSP

Networking

Poster and Cocktail Reception

Break

Breakfast and Poster Set Up

Other

Lived Experience Perspectives

James Cusack, PSPA · Kristophe Diaz, CurePSP

Other

Improving the Patient Experience / Centering Those with PSP and CBD

Boyd Gosh, University Hospital Southampton NHS Foundation Trust

Talk

Caring for the Whole Person in PSP and CBD

Jocelyn Jiao, Stanford University School of Medicine

Talk

Rehabilitation Carepaths: Proactive, Restorative, and Supportive Models of Care

Miriam Rafferty, Shirley Ryan AbilityLab

Talk

Managing Changes in Swallowing and Communication: Balancing Health and Quality of Life

Michelle Troche, Teachers College, Columbia University

Break

Poster and Coffee Break

Other

Genetics

Anne-Marie Wills, Massachusetts General Hospital

Talk

From Genetic Risk to Disease Biology: New Insights into Corticobasal Degeneration

Kurt Farrell, Icahn School of Medicine at Mount Sinai

Talk

CurePSP Genetics Program: Progress and Initial Insights

Sonja Scholz, National Institutes of Health

Talk

Leucine-Rich Repeat Kinase 2 as a Genetic Target That Links Both Genetic and Sporadic Parkinson’s Disease

Mark Cookson, National Institute on Aging

Poster

Lightning Poster Presentations

Jennifer Brummet, CurePSP

Poster

Genetic and Epigenetic Convergence at MOBP Links ALS and PSP

Katherine Fodder, UCL Queen Square Institute of Neurology

Poster

Progressive Supranuclear Palsy in Lebanon: From Epidemiology to Functional Genetics

Jihane Soueid, American University of Beirut

Poster

Multiplex Blood-Based Proteomic Profiling Supports Diagnosis and Reveals Immune Pathways Associated with Clinical Progression and Survival in Progressive Supranuclear Palsy and Corticobasal Syndrome

Meira van Schaik, University of Cambridge

Poster

Apathy, Not Disinhibition, is Associated with Selective Memory Impairment in Progressive Supranuclear Palsy-Richardson Syndrome

Carmela Tartaglia, University of Toronto

Networking

Networking Lunch

Other

Bench to Breakthrough: Preclinical Models for Therapeutic Development

Kat Bowles, UK Dementia Research Institute at The University of Edinburgh

Talk

Phenotypic Small Molecule Screening and Target Confirmation in a Zebrafish PSP model

Edward Burton, University of Pittsburgh School of Medicine

Talk

Patient iPSC Models in Drug Development: Correcting MAPT Splicing to Target 4R Tauopathies

Maria Catarina Silva, Massachusetts General Hospital & Harvard Medical School

Talk

An Integrated Organoid Manufacturing and Phenotyping Platform for Tauopathy Therapeutic Development

Taylor Bertucci, Neural Stem Cell Institute

Talk

Design and Application of Preclinical Studies in Drug Development

Isabel Gonzalez, Drug Discovery and Development Consultants (3D Consultants)

Break

Poster and Coffee Break

Other

Global Cohorts

Huw Morris, UCL Queen Square Institute of Neurology

Talk

Beyond MAPT: Genetic and Biofluid Signatures of PSP in a Taiwanese Cohort

Chin-Hsien Lin, National Taiwan University Hospital

Talk

Expansion of the PROSPECT Cohort - Investigating Incident Parkinsonism Across the UK

Riona Fumi, University College London

Talk

The African iPSC Initiative: Building Genetically Diverse Human Models for Tauopathy Research

Mahmoud Maina, Biomedical Science Research and Training Centre

Talk

The Brazilian Atypical Parkinsonism Study (BRAPS): Building a PSP Cohort in Latin America

Jacy Parmera, University of São Paulo

Other

Closing Remarks and Poster Awards

James Cusack, PSPA · Kristophe Diaz, CurePSP